Neuland Laboratories Announces Strategic Collaboration with Gland Pharma; Boosts Capacity and Reports Q3 Results

Neuland Laboratories Announces Strategic Collaboration with Gland Pharma; Boosts Capacity and Reports Q3 Results​

Neuland Laboratories Limited has announced a major strategic collaboration with Gland Pharma Limited to expand sterile Active Pharmaceutical Ingredient (API) manufacturing capabilities. Beyond this partnership, the company also provided updates on its capacity enhancement plans and released its unaudited financial results for the quarter ended June 30, 2026.

Strategic Partnership with Gland Pharma​

The collaboration is set to create a dedicated manufacturing platform focused on sterile APIs pertaining to microparticle depot products. This partnership combines Neuland's complex API development and manufacturing expertise with Gland Pharma's global sterile manufacturing skills and regulatory compliance track record.

Through the agreement, Gland Pharma will establish an additional dedicated sterile suite at its JNPC facility in Visakhapatnam. The new facility is designed to meet cGMP, USFDA, and EU standards, targeting a capacity of approximately 1400 kg annually, allowing for manufacturing flexibility across various sterile products.

Neuland's CEO & MD, Mr. Saharsh Davuluri, stated that the partnership strengthens Neuland's ability to deliver quality and supply assurance by combining its complex API expertise with Gland Pharma’s proven sterile manufacturing capabilities. Srinivas Sadu, Executive Chairman of Gland Pharma Limited, emphasized that the investment enhances their capacity in sterile API manufacturing, supporting customers with a robust and scalable CDMO solution.

Capacity Enhancement at Unit 1​

Neuland Laboratories is also enhancing its manufacturing infrastructure at Unit 1, located in Bonthapally Village, Sangareddy District, Telangana. The expansion aims to maintain and cater to growing customer demand.

Details of the planned capacity addition are as follows:

• Existing Capacity: 376.5 KL
• Existing Utilization: 91%
• Proposed Addition: 18 KL
• Timeline for Addition: 6 to 7 months
• Investment Required: 39.8 crores (including GST)
• Financing Mode: Internal accruals

Corporate Guarantee and Financial Results Overview​

In a financial transaction approved by the Board of Directors, Neuland committed to executing an irrevocable, unconditional, and continuing Corporate Guarantee of Rs 40 crores in favor of Gland Pharma Limited. This guarantee relates to obligations under a Loan Licence Agreement intended to establish dedicated manufacturing capacity for specific products. The company noted that this corporate guarantee constitutes a contingent liability but has no immediate impact on the financials.

Q3 FY2026 Financial Performance Highlights​

The company's unaudited financial results for the quarter ended June 30, 2026, showed significant performance across various metrics. Below are key takeaways from the consolidated and standalone statements.

Consolidated Financial Results (All figures in lakhs):

Standalone Financial Results (All figures in lakhs):

Segment Reporting Details​

The company provides detailed geographic segment reporting for its consolidated financial results, as per Ind AS Operating Segments.

Segment Revenue (in lakhs):

A review report by MSKA & Associates LLP and an independent auditor's review report were completed for both the consolidated and standalone unaudited financial results.

NEULANDLAB Stock Price Movement​

Today, Neuland Laboratories Limited shares surged to settle at ₹19,956 after post-market trading, celebrating a phenomenal climb and achieving a significant 52-week high. The stock rose by ₹776.00 during the day, with 60,067 shares being traded in the volatile session.